MX2010004537A - Usos de un inhibidor glucoproteina vi (gpvi). - Google Patents

Usos de un inhibidor glucoproteina vi (gpvi).

Info

Publication number
MX2010004537A
MX2010004537A MX2010004537A MX2010004537A MX2010004537A MX 2010004537 A MX2010004537 A MX 2010004537A MX 2010004537 A MX2010004537 A MX 2010004537A MX 2010004537 A MX2010004537 A MX 2010004537A MX 2010004537 A MX2010004537 A MX 2010004537A
Authority
MX
Mexico
Prior art keywords
inhibitor
gpvi
glycoprotein
infarction
invention describes
Prior art date
Application number
MX2010004537A
Other languages
English (en)
Inventor
Yongee Liu
Junichi Kambayashi
Narendra N Tandon
Hisao Takizawa
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of MX2010004537A publication Critical patent/MX2010004537A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención describe un método para reducir el daño por reperfusión y/o el infarto mediante el uso de un inhibidor de la GPVI plaquetaria. Este método puede ser utilizado para tratar a pacientes durante o después de un infarto de miocardio o cirugía cardiaca electiva.
MX2010004537A 2007-10-31 2008-10-29 Usos de un inhibidor glucoproteina vi (gpvi). MX2010004537A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98433407P 2007-10-31 2007-10-31
PCT/US2008/012311 WO2009058326A1 (en) 2007-10-31 2008-10-29 Uses of a glycoprotein vi (gpvi) inhibitor

Publications (1)

Publication Number Publication Date
MX2010004537A true MX2010004537A (es) 2010-05-20

Family

ID=40591365

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010004537A MX2010004537A (es) 2007-10-31 2008-10-29 Usos de un inhibidor glucoproteina vi (gpvi).

Country Status (16)

Country Link
US (1) US20100297116A1 (es)
EP (1) EP2212416A4 (es)
JP (1) JP2011502123A (es)
KR (1) KR20100075585A (es)
CN (1) CN101874107A (es)
AR (1) AR069120A1 (es)
AU (1) AU2008319336A1 (es)
BR (1) BRPI0818807A2 (es)
CA (1) CA2703770A1 (es)
IL (1) IL205453A0 (es)
MX (1) MX2010004537A (es)
RU (1) RU2010121878A (es)
SG (1) SG185307A1 (es)
TW (1) TW200936606A (es)
WO (1) WO2009058326A1 (es)
ZA (1) ZA201002990B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8852593B2 (en) * 2009-12-18 2014-10-07 Sanofi Antagonist antibodies and their fab fragments against GPVI and uses thereof
EP2397495A1 (en) * 2010-06-21 2011-12-21 Sanofi Novel antagonist antibodies and their Fab fragments against GPVI and uses thereof
EP2336188A1 (en) * 2009-12-18 2011-06-22 Sanofi-Aventis Novel antagonist antibodies and their Fab fragments against GPVI and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ302693B6 (cs) * 1999-05-07 2011-09-07 Aventis Pharma Deutschland Gmbh Rekombinantní lidský glykoprotein VI, DNA, která ho kóduje a farmaceutický prostredek, který ho obsahuje
US20040001826A1 (en) * 1999-06-30 2004-01-01 Millennium Pharmaceuticals, Inc. Glycoprotein VI and uses thereof
AU7097400A (en) * 1999-09-01 2001-03-26 Otsuka Pharmaceutical Co., Ltd. Platelet membrane glycoprotein vi (gpvi) dna and protein sequences, and uses thereof
EP1224942A1 (en) * 2001-01-23 2002-07-24 Bernhard Dr. Nieswandt Use of JAQ1 (monoclonal antibody anti GPVI) as a medicament for the protection against thrombotic diseases
GB0130543D0 (en) * 2001-12-20 2002-02-06 Univ Cambridge Tech Human antibodies and their use
EP1369128A1 (en) * 2002-06-07 2003-12-10 Procorde GmbH Inhibitors of glycoprotein VI and their therapeutic use
CA2532781A1 (en) * 2003-07-18 2005-01-27 Mochida Pharmaceutical Co., Ltd The anti-platelet membrane glycoprotein vi monoclonal antibody
US7645592B2 (en) * 2004-04-29 2010-01-12 Otsuka Pharmaceutical Co., Ltd. Glycoprotein VI antibodies and methods of use thereof
KR101194446B1 (ko) * 2004-04-29 2012-10-24 오쓰까 세이야꾸 가부시키가이샤 당단백 ｖｉ에 특이적인 항체 및 그의 제조방법
EP1876240B1 (en) * 2005-04-28 2012-08-22 Mochida Pharmaceutical Co., Ltd. Anti-human platelet membrane glycoprotein vi monoclonal antibody

Also Published As

Publication number Publication date
AR069120A1 (es) 2009-12-30
ZA201002990B (en) 2011-07-27
CA2703770A1 (en) 2009-05-07
CN101874107A (zh) 2010-10-27
WO2009058326A1 (en) 2009-05-07
TW200936606A (en) 2009-09-01
JP2011502123A (ja) 2011-01-20
BRPI0818807A2 (pt) 2014-10-29
AU2008319336A1 (en) 2009-05-07
EP2212416A1 (en) 2010-08-04
RU2010121878A (ru) 2011-12-10
KR20100075585A (ko) 2010-07-02
SG185307A1 (en) 2012-11-29
IL205453A0 (en) 2010-12-30
US20100297116A1 (en) 2010-11-25
EP2212416A4 (en) 2013-01-09

Similar Documents

Publication Publication Date Title
MX2013003634A (es) Derivados policiclicos heterociclicos y metodos de uso de los mismos para el tratamiento de enfermedades virales.
MX2009011002A (es) Composiciones de proteccion de isquemia/reperfusion y metodos de uso.
NZ592854A (en) Crystalline forms of (r)-5-[3-chloro-4-(2,3-dihydroxy-propoxy)-benz[z]ylidene]-2-([z]-propylimino)-3-o-tolyl-thiazolidin-4-one
UA102251C2 (ru) Производные аминодигидротиазина как ингибиторы васе для лечения болезни альцгеймера
BR112015000349A2 (pt) método de tratamento de tumores estromais gastrointestinais
IL193484A0 (en) Gsk-3 inhibitors for the treatment of osteoporosis
IN2012DN00971A (es)
EP2320937A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF OCULAR OXIDATION STRESS AND PIGMENT RETINITY
IN2012DN00624A (es)
EP2279009A4 (en) METHOD AND COMPOSITIONS FOR TREATING OR PREVENTING PATHOLOGICAL CARDIAL REMODELING AND HEART FAILURE
WO2008017025A3 (en) Combination therapy
IL211313A0 (en) Compounds, compositions and methods for the treatment of ??-amyloid diseases and synucleinopathies
IN2012DN01273A (es)
WO2010123527A3 (en) Use of epidermal growth factor inhibitors in the treatment of viral infection
WO2010072787A3 (en) A composition comprising a retinoid and method of treating skin conditions
WO2009150547A3 (en) 2-pyridyl substituted imidazoles as alk4 and/or alk4 inhibitors
IN2012DN02624A (es)
WO2008020904A3 (en) Method for reducing the risk of or preventing infection due to surgical or invasive medical procedures
WO2011127048A3 (en) NON-HORMONAL STEROID MODULATORS OF NF-ĸB FOR TREATMENT OF DISEASE
IL188827A0 (en) Method of treating or preventing tissue deterioration, injury or damage due to congestive heart failure
MX2010004537A (es) Usos de un inhibidor glucoproteina vi (gpvi).
WO2010065861A3 (en) Inhibitors of bace 1 and methods for treating alzheimer's disease
WO2010042212A3 (en) Methods for treating or preventing pain using spicamycin derivatives
EP1784204A4 (en) PROCESS FOR PREPARING, PREVENTING, INHIBITING OR REDUCING DAMAGE TO HEART TISSUE
WO2012082942A3 (en) Neuropeptide analogs, compositions, and methods for treating pain

Legal Events

Date Code Title Description
FG Grant or registration